Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 35 Debt-to-EBITDA is 1.02 as of Jun. 2026. GuruFocus rates BIOE with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 678 Drug Manufacturers companies, Bio Essence ranks better than 62.54% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bio Essence's Debt-to-EBITDA or its related term are showing as below:
BIOE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.29 Med: -5.72 Max: 1.74
Current: 0.95
During the past 7 years, the highest Debt-to-EBITDA Ratio of Bio Essence was 1.74. The lowest was -9.29. And the median was -5.72.
BIOE's Debt-to-EBITDA is ranked better than 62.54% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs BIOE: 0.95
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bio Essence Debt-to-EBITDA Related Terms
Bio Essence Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bio Essence's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOE vs INM, SNOA, CABR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio Essence's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bio Essence (BIOE) has a Debt-to-EBITDA of 1.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bio Essence. According to the industry distribution chart, Bio Essence ranks #254 out of 678 companies in the Drug Manufacturers industry, placing it in the top 37.5%.
Is Bio Essence's Debt-to-EBITDA too high?
Bio Essence's current Debt-to-EBITDA is 1.02. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Bio Essence's value of 1.02 is 37.8% below this industry median. Based on the distribution chart, Bio Essence ranks #254 out of 678 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bio Essence has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Debt-to-EBITDA compare to INM and SNOA?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #254 out of 678 companies for Debt-to-EBITDA. This puts Bio Essence in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Bio Essence's value of 1.02 is 37.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current Debt-to-EBITDA of 1.02 is 37.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bio Essence. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current Debt-to-EBITDA is 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Debt-to-EBITDA of 1.02. The current Debt-to-EBITDA is 1.02 and 37.8% below the Drug Manufacturers industry median of 1.64. Bio Essence's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bio Essence (BIOE), the current Debt-to-EBITDA is 1.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
35GF Score
Get the complete analysis for BIOE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
